Tag: TAK721
Takeda receives full response letter from FDA for TAK-721
Takeda Pharmaceutical Company Limited (TSE: 4502 / NYSE: TAK) (“Takeda”) announced today that it has received a Complete Response Letter (CRL) from the United States Food and Drug Administration (FDA)…